Cargando…

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort

This study aimed to prospectively evaluate clinical, histopathological and molecular variables for outcome prediction in medulloblastoma patients. Patients from the HIT2000 cooperative clinical trial were prospectively enrolled based on the availability of sufficient tumor material and complete clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietsch, Torsten, Schmidt, Rene, Remke, Marc, Korshunov, Andrey, Hovestadt, Volker, Jones, David T. W., Felsberg, Jörg, Kaulich, Kerstin, Goschzik, Tobias, Kool, Marcel, Northcott, Paul A., von Hoff, Katja, von Bueren, André O., Friedrich, Carsten, Mynarek, Martin, Skladny, Heyko, Fleischhack, Gudrun, Taylor, Michael D., Cremer, Friedrich, Lichter, Peter, Faldum, Andreas, Reifenberger, Guido, Rutkowski, Stefan, Pfister, Stefan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059991/ https://www.ncbi.nlm.nih.gov/pubmed/24791927 http://dx.doi.org/10.1007/s00401-014-1276-0

Ejemplares similares

Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
por: Hovestadt, Volker, et al.
Publicado: (2013)

MEDB-61. Genetic alterations ofTP53 andOTX2 indicate increased risk of relapse in WNT medulloblastomas
por: Goschzik, Tobias, et al.
Publicado: (2022)

Molecular subgroups of medulloblastoma: the current consensus
por: Taylor, Michael D., et al.
Publicado: (2011)

MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate
por: Tonn, Svenja, et al.
Publicado: (2022)

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
por: Kool, Marcel, et al.
Publicado: (2012)

MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma
por: Obrecht, Denise, et al.
Publicado: (2022)

MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy – Results of the MET-HIT2000-BIS4 trial
por: Mynarek, Martin, et al.
Publicado: (2022)

Update on molecular and genetic alterations in adult medulloblastoma
por: Kool, Marcel, et al.
Publicado: (2012)

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies
por: Obrecht, Denise, et al.
Publicado: (2022)

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
por: Mynarek, Martin, et al.
Publicado: (2022)

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
por: Gaab, Christine, et al.
Publicado: (2022)

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
por: Sharma, Tanvi, et al.
Publicado: (2019)

MDB-28. DEEP LEARNING-BASED PERSONALIZED SURVIVAL PREDICTION FOR MEDULLOBLASTOMA
por: Stefan, Sabina, et al.
Publicado: (2023)

Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
por: Ottensmeier, Holger, et al.
Publicado: (2020)

Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas
por: Goschzik, Tobias, et al.
Publicado: (2022)

MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT
por: Mynarek, Martin, et al.
Publicado: (2020)

MEDB-17. Re-irradiation for recurrent medulloblastoma in a matched cohort: Advantageous especially in patients without resection
por: Adolph, Jonas E, et al.
Publicado: (2022)

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours
por: von Bueren, A O, et al.
Publicado: (2012)

Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression
por: Korshunov, Andrey, et al.
Publicado: (2022)

The WIP1 Oncogene Promotes Progression and Invasion of Aggressive Medulloblastoma Variants
por: Buss, Meghan C., et al.
Publicado: (2014)

MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?
por: Obrecht, Denise, et al.
Publicado: (2020)

Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples
por: Northcott, Paul A., et al.
Publicado: (2011)

Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells
por: Robson, Jonathan P., et al.
Publicado: (2019)

ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing
por: Jäger, Natalie, et al.
Publicado: (2012)

QOL-24. DIFFERENTIAL IMPACT OF TUMOR LOCATION, LOCAL AND CRANIOSPINAL IRRADIATION ON NEUROPSYCHOLOGICAL LONG-TERM OUTCOME IN CHILDREN WITH MEDULLOBLASTOMA, EPENDYMOMA AND SUPRATENTORIAL PNET: A LONGITUDINAL MULTICENTER OUTCOME ASSESSMENT OF CHILDREN FROM THE HIT-2000 AND HIT-REZ TRIALS
por: Ottensmeier, Holger, et al.
Publicado: (2020)

PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL
por: Hagel, Christian, et al.
Publicado: (2020)

QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL
por: Mynarek, Martin, et al.
Publicado: (2020)

Mitochondrial DNA mutations in Medulloblastoma
por: Funke, Viktoria L. E., et al.
Publicado: (2023)

Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome
por: Jünger, Stephanie T., et al.
Publicado: (2020)

MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor?
por: Schömig, Lena, et al.
Publicado: (2022)

Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma
por: Begemann, Matthias, et al.
Publicado: (2020)

Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses
por: Okonechnikov, Konstantin, et al.
Publicado: (2023)

MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register
por: Tschirner, Sebastian, et al.
Publicado: (2022)

MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS
por: Mynarek, Martin, et al.
Publicado: (2020)

MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort
por: Wolgast, Stella, et al.
Publicado: (2022)

Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment
por: Hill, Rebecca M., et al.
Publicado: (2021)

Group-specific cellular metabolism in Medulloblastoma
por: Funke, Viktoria L. E., et al.
Publicado: (2023)

ETMR-14. TREATMENT OF EMBRYONAL TUMOURS WITH MULTILAYERED ROSETTES (ETMR) WITH CARBOPLATIN-ETOPOSIDE INDUCTION AND TANDEM HIGH-DOSE CHEMOTHERAPY WITHIN THE PROSPECTIVE HIT-TRIALS AND REGISTRIES
por: Juhnke, Björn-Ole, et al.
Publicado: (2020)

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients
por: von Bueren, André O, et al.
Publicado: (2011)

Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas
por: Wolter, Marietta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ipqbucr6fo5rojndsdp7ccrq8m